Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials. Aim: This study compared the effects of vortioxetine and escitalopram on sexual functioning in adults with well-treated MDD experiencing treatment-emergent sexual dysfunction (TESD). Methods: Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vortioxetine (10/20 mg; n = 225) or escitalopram (10/20 mg; n = 222) for 8 weeks. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14), and antidepressant efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI) scale, and Profile of Mood States brief form (POMS-brief). Safety and tolerability were also assessed. Main Outcome Measures: The primary endpoint was change from baseline in the CSFQ-14 total score after 8 weeks of treatment. The MADRS, CGI, and POMS-brief were used to assess antidepressant efficacy. Safety was assessed via adverse events, vital signs, electrocardiograms, laboratory values, weight, and physical examination findings. Results: Vortioxetine showed significantly greater improvements in CSFQ-14 total score (8.8 ± 0.64, mean ± standard error) vs. escitalopram (6.6 ± 0.64; P = 0.013). Benefits vs. escitalopram were significant on four of five dimensions and all three phases of sexual functioning assessed by the CSFQ-14 (P < 0.05). Antidepressant efficacy continued in both groups, with similar, but slight, improvements in MADRS and CGI scores. Vortioxetine and escitalopram had similar clinical efficacy profiles in this study, with safety profiles similar to previous trials. Nausea (n = 9, 4.0%) was the most common treatment-emergent adverse event leading to discontinuation of vortioxetine. Conclusion: Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citationGartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
Keller, A., McGarvey, E. L., & Clayton, A. H. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230500232909 · Cited by 243
Self-citationBoulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Reichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
Research works printed but not linked: 29
- Clayton, 2006, Major depressive disorder, antidepressants, and sexual dysfunction, J Clin Psychiatry, 67, 33
- Corona, 2009, Selective serotonin reuptake inhibitor-induced sexual dysfunction, J Sex Med, 6, 1259, 10.1111/j.1743-6109.2009.01248.x · DOI
- Clayton, 2007, Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder, J Sex Med, 4, 917, 10.1111/j.1743-6109.2007.00520.x · DOI · Paper page
- Delgado, 2005, Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder, J Clin Psychiatry, 66, 686, 10.4088/JCP.v66n0603 · DOI · Paper page
- Montejo, 2001, Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction, J Clin Psychiatry, 62, 10
- Rosen, 1999, Effects of SSRIs on sexual function: A critical review, J Clin Psychopharmacol, 19, 67, 10.1097/00004714-199902000-00013 · DOI · Paper page
- Williams, 2010, Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey, J Psychopharmacol, 24, 489, 10.1177/0269881109102779 · DOI
- Ashton, 1998, Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction, J Sex Marital Ther, 24, 191, 10.1080/00926239808404932 · DOI
- Liang, 2012, 5-HT2A receptor-1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: A prospective exploratory study, J Sex Med, 9, 2009, 10.1111/j.1743-6109.2012.02769.x · DOI
- Sidi, 2012, Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine, J Sex Med, 9, 1392, 10.1111/j.1743-6109.2011.02256.x · DOI
- Clayton, 2014, Sexual dysfunction associated with major depressive disorder and antidepressant treatment, Expert Opin Drug Saf, 13, 1361, 10.1517/14740338.2014.951324 · DOI · Paper page
- Taylor, 2013, Strategies for managing sexual dysfunction induced by antidepressant medication, Cochrane Database Syst Rev
- Higgins, 2010, Antidepressant-associated sexual dysfunction: Impact, effects, and treatment, Drug Healthc Patient Saf, 2, 141, 10.2147/DHPS.S7634 · DOI · Paper page
- Rizvi, 2013, Management strategies for SSRI-induced sexual dysfunction, J Psychiatry Neurosci, 38, E27, 10.1503/jpn.130076 · DOI
- Clayton, 2014, Antidepressants and sexual dysfunction: Mechanisms and clinical implications, Postgrad Med, 126, 91, 10.3810/pgm.2014.03.2744 · DOI
- Baldwin, 2012, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD), Eur Neuropsychopharmacol, 22, 482, 10.1016/j.euroneuro.2011.11.008 · DOI
- Mahableshwarkar, 2013, A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder, Curr Med Res Opin, 29, 217, 10.1185/03007995.2012.761600 · DOI · Paper page
- Guy, 1976, Clinical Global Impressions (028-CGI), 217
- Clayton, 1997, Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ), Psychopharmacol Bull, 33, 747
- Clayton, 1997, The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity, Psychopharmacol Bull, 33, 731
- Montgomery, 1979, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Thase, 2006, A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability, J Clin Psychopharmacol, 26, 482, 10.1097/01.jcp.0000239790.83707.ab · DOI · Paper page
- Jacobsen, 2014, The effect of vortioxetine on sexual dysfunction during the treatment of adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD) [abstract], Poster presented at 54th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP/NCDEU), June 16–19
- Lepola, 2003, Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care, Int Clin Psychopharmacol, 18, 211, 10.1097/01.yic.0000074988.54339.7c · DOI · Paper page
- Wade, 2002, Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care, Int Clin Psychopharmacol, 17, 95, 10.1097/00004850-200205000-00001 · DOI · Paper page
- Bech, 2004, Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression, Int J Neuropsychopharmacol, 7, 283, 10.1017/S1461145704004365 · DOI · Paper page
- Kreilgaard, 2008, Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice, Br J Pharmacol, 155, 276, 10.1038/bjp.2008.243 · DOI · Paper page
- Baldwin, 2006, Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine, J Psychopharmacol, 20, 91, 10.1177/0269881105056666 · DOI · Paper page
- Baldwin, 2013, Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants, Depress Res Treat, 2013, 256841
Cited by
Antidepressant‐induced sexual dysfunction
Rothmore, J. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50522 · Cited by 229
Women’s sexual dysfunction associated with psychiatric disorders and their treatment
Basson, R., & Gilks, T. (2018) · Women's Health · doi:10.1177/1745506518762664 · Cited by 225
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Metadata
- Authors
- Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-01
- Volume
- 12
- Issue
- 10
- Pages
- 2036-2048
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W1917104769
- Cited by
- 116
- References
- 19
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- H. Lundbeck A/S
- Takeda Pharmaceutical Company Ltd.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. https://app.cochat.ai/papers/10.1111/jsm.12980
- The paper
- Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H. (2015). Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. The Journal of Sexual Medicine. https://doi.org/10.1111/jsm.12980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.